000302810 001__ 302810
000302810 005__ 20250720021357.0
000302810 0247_ $$2doi$$a10.1186/s13148-025-01918-9
000302810 0247_ $$2pmid$$apmid:40611182
000302810 0247_ $$2pmc$$apmc:PMC12225191
000302810 0247_ $$2ISSN$$a1868-7075
000302810 0247_ $$2ISSN$$a1868-7083
000302810 0247_ $$2altmetric$$aaltmetric:179281169
000302810 037__ $$aDKFZ-2025-01350
000302810 041__ $$aEnglish
000302810 082__ $$a610
000302810 1001_ $$0P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aYuan, Tanwei$$b0$$eFirst author$$udkfz
000302810 245__ $$aMethylation-based smoking signatures in blood and tissue samples for the prediction of self-reported smoking status and mortality in patients with colorectal cancer.
000302810 260__ $$a[Erscheinungsort nicht ermittelbar]$$bBioMed Central$$c2025
000302810 3367_ $$2DRIVER$$aarticle
000302810 3367_ $$2DataCite$$aOutput Types/Journal article
000302810 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1752657706_10337
000302810 3367_ $$2BibTeX$$aARTICLE
000302810 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000302810 3367_ $$00$$2EndNote$$aJournal Article
000302810 500__ $$a#EA:C070#LA:C070#
000302810 520__ $$aSmoking is a well-established risk factor for colorectal cancer (CRC) development. However, the reliability of DNA methylation-based smoking signatures in predicting smoking status and their prognostic value in CRC remain unclear, particularly across different biological sample types.Five previously validated methylation-based smoking signatures were analyzed in 2237 CRC patients with blood-derived DNA and 2273 patients with tumor tissue-derived DNA. Blood-derived signatures showed strong correlations with self-reported smoking status, effectively differentiating current smokers from never smokers (all p < 0.0001), with excellent discriminative ability (median area under the receiver operating characteristic curve: 0.94). In contrast, tumor tissue-derived signatures exhibited much weaker associations with smoking status. Among non-metastatic CRC patients, blood-derived methylation signatures were significantly associated with increased risks of all-cause and non-CRC-related mortality, but not with CRC-specific mortality. Conversely, two tumor tissue-derived signatures demonstrated stronger associations with CRC-specific mortality compared to blood-derived signatures.Blood-derived methylation-based smoking signatures are robust indicators for smoking exposure and are associated with increased mortality risk among non-metastatic CRC patients. When applied to tumor tissue, signatures showed stronger associations with CRC-specific mortality.
000302810 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000302810 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000302810 650_7 $$2Other$$aColorectal cancer
000302810 650_7 $$2Other$$aDNA methylation biomarkers
000302810 650_7 $$2Other$$aPrognosis
000302810 650_7 $$2Other$$aSmoking
000302810 650_2 $$2MeSH$$aHumans
000302810 650_2 $$2MeSH$$aColorectal Neoplasms: genetics
000302810 650_2 $$2MeSH$$aColorectal Neoplasms: mortality
000302810 650_2 $$2MeSH$$aColorectal Neoplasms: blood
000302810 650_2 $$2MeSH$$aDNA Methylation
000302810 650_2 $$2MeSH$$aMale
000302810 650_2 $$2MeSH$$aFemale
000302810 650_2 $$2MeSH$$aMiddle Aged
000302810 650_2 $$2MeSH$$aSmoking: genetics
000302810 650_2 $$2MeSH$$aSmoking: adverse effects
000302810 650_2 $$2MeSH$$aSmoking: blood
000302810 650_2 $$2MeSH$$aSelf Report
000302810 650_2 $$2MeSH$$aAged
000302810 650_2 $$2MeSH$$aPrognosis
000302810 650_2 $$2MeSH$$aRisk Factors
000302810 7001_ $$aTagscherer, Katrin E$$b1
000302810 7001_ $$aRoth, Wilfried$$b2
000302810 7001_ $$0P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aBewerunge-Hudler, Melanie$$b3$$udkfz
000302810 7001_ $$aBrobeil, Alexander$$b4
000302810 7001_ $$aKloor, Matthias$$b5
000302810 7001_ $$aBläker, Hendrik$$b6
000302810 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$udkfz
000302810 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$eLast author$$udkfz
000302810 773__ $$0PERI:(DE-600)2553921-8$$a10.1186/s13148-025-01918-9$$gVol. 17, no. 1, p. 113$$n1$$p113$$tClinical epigenetics$$v17$$x1868-7075$$y2025
000302810 909CO $$ooai:inrepo02.dkfz.de:302810$$pVDB
000302810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000302810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000302810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000302810 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000302810 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000302810 9141_ $$y2025
000302810 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:36:11Z
000302810 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:36:11Z
000302810 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:36:11Z
000302810 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIGENETICS : 2022$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN EPIGENETICS : 2022$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-06
000302810 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-06
000302810 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000302810 9201_ $$0I:(DE-He78)W110-20160331$$kW110$$lMicroarrays$$x0
000302810 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000302810 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x2
000302810 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000302810 980__ $$ajournal
000302810 980__ $$aVDB
000302810 980__ $$aI:(DE-He78)W110-20160331
000302810 980__ $$aI:(DE-He78)HD01-20160331
000302810 980__ $$aI:(DE-He78)C070-20160331
000302810 980__ $$aUNRESTRICTED